Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027
The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.
“The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period”
On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.
In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .
“Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period”
By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.
“The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period”
Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.
In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.
“The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.”
The Hemato oncology testing market is segmented into - North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.
A breakdown of the primary participants referred to for this report is provided below:
This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
“The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period”
On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.
In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .
“Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period”
By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.
“The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period”
Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.
In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.
“The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.”
The Hemato oncology testing market is segmented into - North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–45%, Tier 2–35%, and Tier 3– 45%
- By Designation: C-level–32%, Director-level–20%, and Others–48%
- By Region: North America–35%, Europe–28%, Asia Pacific–25%, ROW¬—12%
- Abbott Laboratories (US)
- F. Hoffman-La Roche (Switzerland)
- QIAGEN (Germany)
- Thermo Fisher Scientific (US)
- Illumina (US)
- Bio-Rad Laboratories (US)q
- MolecularMD (Ireland)
- ArcherDX (US)
- ARUP Laboratories (US)
- Asuragen (US)
- Invivoscribe (US)
- Adaptive Biotechnologies (US)
- Amoy Diagnostics (China)
- ELITechGroup (France)
- Vela Diagnostics (Singapore)
- Gentronix (UK)
- BioIVT (US)
- SAGA Diagnostics (Sweden)
- Olink (Sweden)
- Cancer Diagnostics (US)
This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 MARKETS COVERED
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCES
2.2.2 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.3.2 KEY INDUSTRY INSIGHTS
2.4 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.5 MARKET SIZE ESTIMATION
FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
2.5.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.5.2 TOP-DOWN APPROACH
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.7 RESEARCH ASSUMPTIONS
2.8 STUDY ASSUMPTIONS
2.9 INDICATORS AND OTHER ASSUMPTIONS
2.10 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.11 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW
FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021)
FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021
4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET
FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing incidence of hematologic cancer
TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020–2040
TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030
5.2.1.2 Increasing collaborations between companies
5.2.1.3 Rising number of private diagnostic centers
5.2.1.4 Increasing conferences on personalized medicine
TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests
5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019
TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040
5.2.3.2 Drug diagnostics co-development
5.2.4 CHALLENGES
5.2.4.1 Intellectual property rights protection issues
5.2.4.2 Shortage of trained professionals
6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 SERVICES
6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3 ASSAY KITS
6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH
TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE
7.1 INTRODUCTION
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
7.2 LEUKEMIA
FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
7.2.1 ACUTE MYELOID LEUKEMIA
7.2.1.1 High incidence of AML in adults to drive growth
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
7.2.2.1 High incidence of ALL in children to support growth
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.3 OTHER LEUKEMIAS
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
7.3 LYMPHOMA
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 NON-HODGKIN LYMPHOMA
7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period
FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.3.2 HODGKIN LYMPHOMA
7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate
FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.4 OTHER CANCERS
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 PCR
8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)
8.3 IHC
8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020–2027 (USD MILLION)
8.4 NGS
8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
8.5 CYTOGENETICS
8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020–2027 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 CLINICAL LABORATORIES
9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.3 HOSPITALS
9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER END USERS
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period
TABLE 42 US: LEUKEMIA AT A GLANCE
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET
11.3 MARKET SHARE ANALYSIS, 2021
TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION
11.4 COMPANY EVALUATION MATRIX
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
11.5 KEY STRATEGIES
11.5.1 PRODUCT LAUNCHES
TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019–NOVEMBER 2022
11.5.2 DEALS
TABLE 81 KEY DEALS, JANUARY 2019–AUGUST 2022
11.5.3 OTHER DEVELOPMENTS
TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019–NOVEMBER 2022
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES
TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
12.1.3 QIAGEN N.V.
TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.4 THERMO FISHER SCIENTIFIC, INC.
TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.5 ILLUMINA, INC.
TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES, INC.
TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
TABLE 89 ICON PLC: BUSINESS OVERVIEW
FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021)
12.1.8 ADAPTIVE BIOTECHNOLOGIES
TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)
TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW
12.1.10 ARUP LABORATORIES, INC.
TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW
12.1.11 ASURAGEN, INC.
TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW
12.1.12 INVIVOSCRIBE, INC.
TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
12.1.13 AMOY DIAGNOSTICS CO., LTD.
TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW
12.1.14 ELITECHGROUP
TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW
12.1.15 VELA DIAGNOSTICS
TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 GENTRONIX LIMITED
12.2.2 BIOIVT
12.2.3 SAGA DIAGNOSTICS
12.2.4 OLINK
12.2.5 CANCER DIAGNOSTICS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View
(Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 MARKETS COVERED
1.3.1 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCES
2.2.2 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.3.1 KEY DATA FROM PRIMARY SOURCES
2.3.2 KEY INDUSTRY INSIGHTS
2.4 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.5 MARKET SIZE ESTIMATION
FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
2.5.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.5.2 TOP-DOWN APPROACH
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.7 RESEARCH ASSUMPTIONS
2.8 STUDY ASSUMPTIONS
2.9 INDICATORS AND OTHER ASSUMPTIONS
2.10 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.11 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW
FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021)
FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021
4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET
FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing incidence of hematologic cancer
TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020–2040
TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030
5.2.1.2 Increasing collaborations between companies
5.2.1.3 Rising number of private diagnostic centers
5.2.1.4 Increasing conferences on personalized medicine
TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests
5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019
TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040
5.2.3.2 Drug diagnostics co-development
5.2.4 CHALLENGES
5.2.4.1 Intellectual property rights protection issues
5.2.4.2 Shortage of trained professionals
6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2 SERVICES
6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3 ASSAY KITS
6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH
TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE
7.1 INTRODUCTION
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
7.2 LEUKEMIA
FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
7.2.1 ACUTE MYELOID LEUKEMIA
7.2.1.1 High incidence of AML in adults to drive growth
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
7.2.2.1 High incidence of ALL in children to support growth
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
7.2.3 OTHER LEUKEMIAS
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
7.3 LYMPHOMA
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
7.3.1 NON-HODGKIN LYMPHOMA
7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period
FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.3.2 HODGKIN LYMPHOMA
7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate
FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
7.4 OTHER CANCERS
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2 PCR
8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)
8.3 IHC
8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020–2027 (USD MILLION)
8.4 NGS
8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
8.5 CYTOGENETICS
8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020–2027 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 CLINICAL LABORATORIES
9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.3 HOSPITALS
9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
9.5 OTHER END USERS
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period
TABLE 42 US: LEUKEMIA AT A GLANCE
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET
11.3 MARKET SHARE ANALYSIS, 2021
TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION
11.4 COMPANY EVALUATION MATRIX
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
11.5 KEY STRATEGIES
11.5.1 PRODUCT LAUNCHES
TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019–NOVEMBER 2022
11.5.2 DEALS
TABLE 81 KEY DEALS, JANUARY 2019–AUGUST 2022
11.5.3 OTHER DEVELOPMENTS
TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019–NOVEMBER 2022
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES
TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
12.1.3 QIAGEN N.V.
TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
12.1.4 THERMO FISHER SCIENTIFIC, INC.
TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.5 ILLUMINA, INC.
TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES, INC.
TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
TABLE 89 ICON PLC: BUSINESS OVERVIEW
FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021)
12.1.8 ADAPTIVE BIOTECHNOLOGIES
TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)
TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW
12.1.10 ARUP LABORATORIES, INC.
TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW
12.1.11 ASURAGEN, INC.
TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW
12.1.12 INVIVOSCRIBE, INC.
TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
12.1.13 AMOY DIAGNOSTICS CO., LTD.
TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW
12.1.14 ELITECHGROUP
TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW
12.1.15 VELA DIAGNOSTICS
TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 GENTRONIX LIMITED
12.2.2 BIOIVT
12.2.3 SAGA DIAGNOSTICS
12.2.4 OLINK
12.2.5 CANCER DIAGNOSTICS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View
(Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
